T3 Pharmaceuticals AG

Developing the next generation bacterial cancer therapy The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria. T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of live bacteria. While the technology has diverse applications in research, T3 Pharma has further developed the system to serve as a novel therapeutic to treat solid tumors.

Website

http://www.t3pharma.com

Externer Link zu T3 Pharmaceuticals AG

Branche

Biotechnologieforschung

Größe

11–50 Beschäftigte

Hauptsitz

Basel, BS

Art

Privatunternehmen

Gegründet

2015

Spezialgebiete

Biotechnology, Cancer therapy, Protein delivery und Bacterial cancer therapy